Bristol-Myers Squibb(DE:BRM)
€56.00-0.92 (-1.62%)
DE:BRM
Bristol-Myers Squibb stock forecast
€56.00
At close:-0.92 (-1.62%)
Bristol-Myers Squibb (BRM) Stock Forecast & Price Target
20 Followers
BRM Analyst Ratings
Moderate Buy
8Buy11Hold1Sell
Based on 20 analysts giving stock ratings to Bristol-Myers Squibb in the past 3 months
BRM Stock 12 Month Forecast
Average Price Target
EUR 58.57â–²(4.60% Upside)Based on 20 Wall Street analysts offering 12 month price targets for Bristol-Myers Squibb in the last 3 months. The average price target is EUR 58.57 with a high forecast of EUR 71.28 and a low forecast of EUR 35.64. The average price target represents a 4.60% change from the last price of EUR 56.00.
Past 12 Months12 Month ForecastJan2026Oct2026
HighEUR 71.28
AverageEUR 58.57
LowEUR 35.64
Highest Price TargetHighestEUR 71.28Average Price TargetEUR 58.57Lowest Price TargetLowestEUR 35.64
Detailed List of Analyst Forecasts​
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Evan Seigerman | BMO Capital | EUR 53.46 | hold | -4.53%Downside | Reiterated | 11/09/26 | ||
| Trung Huynh | RBC Capital | EUR 57.03 | hold | 1.83%Upside | Reiterated | 11/05/26 | ||
| Courtney Breen | Bernstein | EUR 54.35 | hold | -2.94%Downside | Reiterated | 11/02/26 | ||
| Louise Chen | Scotiabank | EUR 53.46 | hold | -4.53%Downside | Reiterated | 10/30/26 | ||
| Terence Flynn | Morgan Stanley | EUR 36.53→EUR 35.64 | sell | -36.35%Downside | Reiterated | 10/30/26 | ||
| Mohit Bansal | Wells Fargo | EUR 57.92→EUR 53.46 | hold | -4.53%Downside | Reiterated | 10/30/26 | ||
| Emily Field | Barclays | EUR 66.83 | buy | 19.34%Upside | Reiterated | 10/29/26 | ||
| Matt Phipps | William Blair | ― | hold | ― | Reiterated | 10/29/26 | ||
| Jason Gerberry | Bank of America Securities | EUR 58.81→EUR 59.70 | buy | 6.61%Upside | Reiterated | 10/29/26 | ||
| Seamus Fernandez | Guggenheim | EUR 66.83 | buy | 19.34%Upside | Reiterated | 10/29/26 | ||
| Carter Gould | Cantor Fitzgerald | EUR 47.23 | hold | -15.67%Downside | Reiterated | 10/29/26 | ||
| David Amsellem | Piper Sandler | EUR 69.50 | buy | 24.11%Upside | Reiterated | 10/27/26 | ||
| Asad Haider | Goldman Sachs | EUR 56.14 | hold | 0.24%Upside | Assigned | 10/19/26 | ||
| Geoff Meacham | Citi | EUR 62.37 | hold | 11.38%Upside | Reiterated | 10/13/26 | ||
| Srikripa Devarakonda | Truist Financial | EUR 62.37 | buy | 11.38%Upside | Reiterated | 10/13/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Evan SeigermanBMO Capital | HoldReiteratedEUR 53.46 | 11/09/26 | -4.53%Downside | ||
| Trung HuynhRBC Capital | HoldReiteratedEUR 57.03 | 11/05/26 | 1.83%Upside | ||
| Courtney BreenBernstein | HoldReiteratedEUR 54.35 | 11/02/26 | -2.94%Downside | ||
| Louise ChenScotiabank | HoldReiteratedEUR 53.46 | 10/30/26 | -4.53%Downside | ||
| Terence FlynnMorgan Stanley | SellReiteratedEUR 36.53→EUR 35.64 | 10/30/26 | -36.35%Downside | ||
| Mohit BansalWells Fargo | HoldReiteratedEUR 57.92→EUR 53.46 | 10/30/26 | -4.53%Downside | ||
| Emily FieldBarclays | BuyReiteratedEUR 66.83 | 10/29/26 | 19.34%Upside | ||
| Matt PhippsWilliam Blair | HoldReiterated | 10/29/26 | ― | ||
| Jason GerberryBank of America Securities | BuyReiteratedEUR 58.81→EUR 59.70 | 10/29/26 | 6.61%Upside | ||
| Seamus FernandezGuggenheim | BuyReiteratedEUR 66.83 | 10/29/26 | 19.34%Upside | ||
| Carter GouldCantor Fitzgerald | HoldReiteratedEUR 47.23 | 10/29/26 | -15.67%Downside | ||
| David AmsellemPiper Sandler | BuyReiteratedEUR 69.50 | 10/27/26 | 24.11%Upside | ||
| Asad HaiderGoldman Sachs | HoldAssignedEUR 56.14 | 10/19/26 | 0.24%Upside | ||
| Geoff MeachamCiti | HoldReiteratedEUR 62.37 | 10/13/26 | 11.38%Upside | ||
| Srikripa DevarakondaTruist Financial | BuyReiteratedEUR 62.37 | 10/13/26 | 11.38%Upside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Bristol-Myers Squibb
3 Months
Success Rate13/17 ratings generated profit
76%
Average Return
+9.64%
Copying Srikripa Devarakonda's trades and holding each position for 3 Months would result in 76.47% of your transactions generating a profit, with an average return of +9.64% per trade.
1 Year
Success Rate11/13 ratings generated profit
85%
Average Return
+19.59%
Copying David Amsellem's trades and holding each position for 1 Year would result in 84.62% of your transactions generating a profit, with an average return of +19.59% per trade.
2 Years
Success Rate16/17 ratings generated profit
94%
Average Return
+28.37%
Copying Srikripa Devarakonda's trades and holding each position for 2 Years would result in 94.12% of your transactions generating a profit, with an average return of +28.37% per trade.
BRM Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 22 | 21 | 16 | 20 | 14 |
| Hold | 30 | 28 | 33 | 39 | 33 |
| Sell | 2 | 2 | 3 | 5 | 4 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 54 | 51 | 52 | 64 | 51 |
In the current month, BRM has received 14 Buy Ratings, 33 Hold Ratings, and 4 Sell Ratings. BRM average Analyst price target in the past 3 months is 58.57.
BRM Financial Forecast
HighEUR 1.45
ConsensusEUR 1.34
LowEUR 1.17
BRM Earnings Forecast
Next quarter’s earnings estimate for BRM is EUR 1.34 with a range of EUR 1.17 to EUR 1.45. The previous quarter’s EPS was EUR 1.20. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighEUR 11.6B
ConsensusEUR 11.3B
LowEUR 11.1B
BRM Sales Forecast
Next quarter’s sales forecast for BRM is EUR 11.27B with a range of EUR 11.07B to EUR 11.61B. The previous quarter’s sales results were EUR 11.65B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
BRM Stock Forecast FAQ
What is DE:BRM’s average 12-month price target, according to analysts?
Based on analyst ratings, Bristol-Myers Squibb’s 12-month average price target is €58.57.
What is DE:BRM’s upside potential, based on the analysts’ average price target?
Bristol-Myers Squibb has 4.60% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Bristol-Myers Squibb a Buy, Sell or Hold?
Bristol-Myers Squibb has a consensus rating of Moderate Buy, which is based on 8 buy ratings, 11 hold ratings and 1 sell ratings.
What is Bristol-Myers Squibb’s share price target?
The average share price target for Bristol-Myers Squibb is €58.57. This is based on 20 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €71.28, and the lowest forecast is €35.64. The average share price target represents a 4.60% increase from the current price of €56.
What do analysts say about Bristol-Myers Squibb?
Bristol-Myers Squibb’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 20 Wall Street analysts.
How can I buy shares of Bristol-Myers Squibb?
To buy shares of DE:BRM, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
